Vertex takes two CFTR correctors to Phase III

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it will begin a series of Phase III combination trials in patients with cystic fibrosis evaluating two of its next-generation correctors of cystic fibrosis transmembrane conductance regulator. The company also announced

Read the full 361 word article

User Sign In